Marquam Oliver
Infectious Disease · Salt Lake City, UTNPI 1760400865
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 248 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,598 and has fallen 98.7% since, to $21 in 2025.
Across 248 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$795
- Viiv Healthcare Company$789
- AbbVie$427
- Boehringer Ingelheim$302
- Gilead$289
- Lilly USA, LLC$153
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,892100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 55 | $795 |
| Viiv Healthcare Company | 30 | $789 |
| AbbVie(2 entities) | 39 | $427 |
| Boehringer Ingelheim | 18 | $302 |
| Gilead | 16 | $289 |
| Lilly USA, LLC | 14 | $153 |
| Sanofi-aventis U.S. LLC | 9 | $130 |
| Insmed, Inc. | 8 | $121 |
| Amgen(2 entities) | 8 | $117 |
| Novo Nordisk | 8 | $97 |
| Johnson & Johnson(2 entities) | 6 | $89 |
| Lifescan, Inc. | 6 | $83 |
| Pfizer | 4 | $67 |
| AstraZeneca | 4 | $57 |
| GSK | 3 | $47 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $33 |
| Sanofi Pasteur Inc. | 2 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $17 |
| Mannkind Corporation | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Shionogi Inc | 1 | $15 |
| Antares Pharma, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
| Melinta Therapeutics, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,892 in reported general payments places this provider in the 85th percentile of 44 infectious disease providers in Utah.
Other infectious disease in Salt Lake City
- William TettelbachSalt Lake City$82K
- Kimberly HansonSalt Lake City$22K
- Bert LopansriSalt Lake City$20K
- David ClassenSalt Lake City$14K
- Andrew SkinnerSalt Lake City$10K
- Adam SpivakSalt Lake City$5K
- Joel TrachtenbergSalt Lake City$2K
- Emily Sydnor SpivakSalt Lake City$1K
- Sankar SwaminathanSalt Lake City$800
- Patricia Ruggeri-WeigelSalt Lake City$737
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.